Soumit Roy
Stock Analyst at Jones Trading
(3.46)
# 963
Out of 5,116 analysts
44
Total ratings
32.35%
Success rate
12.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WHWK Whitehawk Therapeutics | Initiates: Buy | $7 | $2.67 | +162.17% | 1 | Dec 22, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $7 | $1.13 | +519.47% | 1 | Dec 22, 2025 | |
| EVAX Evaxion | Initiates: Buy | $10 | $5.13 | +94.93% | 1 | Oct 30, 2025 | |
| AVXL Anavex Life Sciences | Downgrades: Hold | n/a | $3.64 | - | 1 | Oct 24, 2025 | |
| CGON CG Oncology | Initiates: Buy | $50 | $39.84 | +25.50% | 1 | Sep 8, 2025 | |
| TARA Protara Therapeutics | Initiates: Buy | $21 | $5.55 | +278.38% | 1 | May 22, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $40 | $21.97 | +82.07% | 1 | May 20, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Buy | $36 → $27 | $16.30 | +65.64% | 2 | May 16, 2025 | |
| ACRV Acrivon Therapeutics | Downgrades: Hold | n/a | $2.44 | - | 2 | May 16, 2025 | |
| ONCY Oncolytics Biotech | Downgrades: Hold | n/a | $0.95 | - | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $8.08 | +85.64% | 3 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $9.40 | +6.38% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $34 | $27.98 | +21.52% | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $2.23 | +1,514.35% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $2.80 | +1,042.86% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $8.07 | +11.52% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $8.25 | +106.06% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.17 | +499.08% | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $4 | $0.52 | +669.23% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.18 | - | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.33 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $10.37 | +150.72% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $14.25 | +391.23% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $68.66 | -85.44% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $6.59 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $14.65 | +446.08% | 1 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.00 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $1.42 | +22,435.21% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $4.23 | +19,048.94% | 1 | Feb 24, 2021 |
Whitehawk Therapeutics
Dec 22, 2025
Initiates: Buy
Price Target: $7
Current: $2.67
Upside: +162.17%
Context Therapeutics
Dec 22, 2025
Initiates: Buy
Price Target: $7
Current: $1.13
Upside: +519.47%
Evaxion
Oct 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.13
Upside: +94.93%
Anavex Life Sciences
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $3.64
Upside: -
CG Oncology
Sep 8, 2025
Initiates: Buy
Price Target: $50
Current: $39.84
Upside: +25.50%
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $5.55
Upside: +278.38%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $21.97
Upside: +82.07%
Enliven Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $16.30
Upside: +65.64%
Acrivon Therapeutics
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.44
Upside: -
Oncolytics Biotech
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.95
Upside: -
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $8.08
Upside: +85.64%
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $9.40
Upside: +6.38%
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $27.98
Upside: +21.52%
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $2.23
Upside: +1,514.35%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $2.80
Upside: +1,042.86%
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $8.07
Upside: +11.52%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $8.25
Upside: +106.06%
Sep 17, 2024
Initiates: Buy
Price Target: $13
Current: $2.17
Upside: +499.08%
Sep 11, 2024
Maintains: Buy
Price Target: $6 → $4
Current: $0.52
Upside: +669.23%
Jul 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.18
Upside: -
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $5.33
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $10.37
Upside: +150.72%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $14.25
Upside: +391.23%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $68.66
Upside: -85.44%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $6.59
Upside: -
Apr 19, 2023
Initiates: Buy
Price Target: $80
Current: $14.65
Upside: +446.08%
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.00
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $1.42
Upside: +22,435.21%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $4.23
Upside: +19,048.94%